Moderna unveils positive data from its Phase 1 mRNA-1273 vaccine trial
Moderna is engaged in developing messenger RNA (mRNA) therapeutics and vaccines for advanced transformative medicines for patients
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
19 May 20
Moderna is engaged in developing messenger RNA (mRNA) therapeutics and vaccines for advanced transformative medicines for patients
19 May 20
Enhertu is indicated for the treatment of metastatic in patients whose tumours have a HER2 mutation and with…
18 May 20
QINLOCK has been indicated for GIST in adult patients who have received prior treatment with three or more…
18 May 20
The preliminary data from the clinical study of nine ambulatory boys with DMD demonstrated positive results for the…
15 May 20
The approval is based on results of from Phase 3 ECHELON-2 trial, which showed that treatment with ADCETRIS…
14 May 20
Remdesivir is an investigational medicine that has been granted the US Food and Drug Administration (FDA) EUA to…
14 May 20
KEYTRUDA is a humanised monoclonal antibody designed to block the interaction between PD-1 to activate the T lymphocytes
13 May 20
Moderna designed the new mRNA-1273 is an mRNA vaccine to work against SARS-CoV-2 encoding for a prefusion stabilised…
12 May 20
Lynparza is an advanced PARP inhibitor and the targeted treatment to block DNA damage response (DDR) in cells…
12 May 20
Thermo Fisher’s $180m expansion project would increase its commercial viral vector capacity by more than double and support…